Pheochromocytoma/paraganglioma type 5 syndrome as a cause of secondary hypertension in a Colombian patient: case report
Abstract
Pheochromocytoma is a tumor derived from neural crest cells able to produce sympathomimetic substances and, hence, a particular clinical picture. It is responsible
for less than 1% of high blood pressure cases, with an estimated incidence between 0.4 and 0.6 cases per 100,000 people each year, and an average survival of seven years. Pheochromocytoma is a solid tumor with a high genetic component, as heritability can reach 40%. Once diagnosed, its treatment and prognosis are partly conditioned by the associated pathogenic variants that can be documented, especially those related to RET, SDHx, VHL, and NF1 genes.
We present the case of a young woman with abdominal pain and high blood pressure, who was found to have a pheochromocytoma. Genetic testing detected a rare and recently discovered pathogenic variant: the SDHA:c.1A>C (p.Met1Leu). The patient responded adequately to the surgical treatment and continued the follow-up without documented recurrences.
The diagnostic approach for pheochromocytoma patients must start with a clinical suspicion, followed by metabolite measurement in blood and urine, and finally, imaging. Currently, technology development allows precision medicine applicability. In this case of pheochromocytoma, recent developments in precision medicine resulted in the detection of associated genetic components involving the patient and her family. Adequate screening of the index patient is required for documenting pathogenic variants and better characterizing the disease.
Downloads
References
Dahia PL. Pheochromocytoma and paraganglioma pathogenesis: Learning from genetic heterogeneity. Nat Rev Cancer. 2014;14:108-19. https://doi.org/10.1038/nrc3648
Berends AM, Buitenwerf E, de Krijger RR, Veeger NJ, van der Horst-Schrivers AN, Links TP, et al. Incidence of pheochromocytoma and sympathetic paraganglioma in the Netherlands: A nationwide study and systematic review. Eur J Intern Med. 2018;51:68-73. https://doi.org/10.1016/j.ejim.2018.01.015
Neumann HP, Young Jr WF, Eng C. Pheochromocytoma and paraganglioma. N Engl J Med. 2019;381:552-65. https://doi.org/10.1056/NEJMra1806651
Navarro EP, Osejo MC, Casas LA, Arango LG, Guzmán G. Experiencia en el manejo de feocromocitoma en los últimos 10 años: serie de casos. Rev Colomb Endocrinol Diabet Metab. 2016;3:33-6. https://doi.org/10.53853/encr.3.3.39
Fränkel F. A case of bilateral, completely latent adrenal tumor and concurrent nephritis with changes in the circulatory system and retinitis. CA Cancer J Clin. 1984;34:93-106. https://doi.org/10.3322/canjclin.34.2.93
Liu Z, Ma J, Jiménez C, Zhang M. Pheochromocytoma: A clinicopathologic and molecular study of 390 cases from a single center. Am J Surg Pathol. 2021;45:1155-65. https://doi.org/10.1097/PAS.0000000000001768
Bausch B, Schiavi F, Ni Y, Welander J, Patocs A, Ngeow J, et al. Clinical characterization of the pheochromocytoma and paraganglioma susceptibility genes SDHA, TMEM127, MAX, and SDHAF2 for gene-informed prevention. JAMA Oncol. 2017;3:1204-12. https://doi.org/10.1001/jamaoncol.2017.0223
Nölting S, Ullrich M, Pietzsch J, Ziegler CG, Eisenhofer G, Grossman A, et al. Current management of pheochromocytoma/paraganglioma: A guide for the practicing clinician in the era of precision medicine. Cancers. 2019;11:1505. https://doi.org/10.3390/cancers11101505
Lenders JW, Duh Q-Y, Eisenhofer G, Gimenez-Roqueplo A-P, Grebe SK, Murad MH, et al. Pheochromocytoma and paraganglioma: An endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2014;99:1915-42. https://doi.org/10.1210/jc.2014-1498
Jha A, De Luna K, Balili CA, Millo C, Paraiso CA, Ling A, et al. Clinical, diagnostic, and treatment characteristics of SDHA-related metastatic pheochromocytoma and paraganglioma. Front Oncol. 2019;9:53. https://doi.org/10.3389/fonc.2019.00053
Burnichon N, Brière J-J, Libé R, Vescovo L, Riviere J, Tissier F, et al. SDHA is a tumor suppressor gene causing paraganglioma. Hum Mol Genet. 2010;19:3011-20. https://doi.org/10.1093/hmg/ddq206
Molina L, Salgado J, Amado S. Feocromocitoma y paraganglioma: un reto más allá de la clínica. Rev Colomb Cancerol. 2021;25:3-12. https://doi.org/10.35509/01239015.586
Vasconcelos-Prado OD, López-García AE, García-Montalvo IA. Aspectos genéticos de los feocromocitomas y paragangliomas. J Negat No Posit Results. 2021;6:636-50. https://doi.org/10.19230/jonnpr.4020
Rueda-Galvis MV, Román-Gonzaléz A, Agredo-Delgado V. Síndrome de feocromocitomaparaganglioma tipo 5 asociado a mutación en el complejo de la succinato deshidrogenasa tipo A (SDHA), a propósito de un caso. Iatreia. 2023;36. https://doi.org/10.17533/udea.iatreia.187
Welander J, Garvin S, Bohnmark R, Isaksson L, Wiseman RW, Söderkvist P, et al. Germline SDHA mutation detected by next-generation sequencing in a young index patient with large paraganglioma. J Clin Endocrinol Metab. 2013;98:e1379-80. https://doi.org/10.1210/jc.2013-1963
van Der Tuin K, Mensenkamp AR, Tops CM, Corssmit EP, Dinjens WN, van de Horst-Schrivers AN, et al. Clinical aspects of SDHA-related pheochromocytoma and paraganglioma: A nationwide study. J Clin Endocrinol Metab. 2018;103:438-45. https://doi.org/10.1210/jc.2017-01762
Amar L, Pacak K, Steichen O, Akker SA, Aylwin SJ, Baudin E, et al. International consensus on initial screening and follow-up of asymptomatic SDHx mutation carriers. Nat Rev Endocrinol. 2021;17:435-44. https://doi.org/10.1038/s41574-021-00492-3
Taïeb D, Hicks RJ, Hindié E, Guillet BA, Avram A, Ghedini P, et al. European association of nuclear medicine practice guideline/society of nuclear medicine and molecular imaging procedure standard 2019 for radionuclide imaging of phaeochromocytoma and paraganglioma. Eur J Nucl Med Mol Imaging. 2019;46:2112-37. https://doi.org/10.1007/s00259-019-04398-1
Some similar items:
- Mario Francisco Guerrero, Elements for the effective evaluation of natural products with possible antihypertensive effects , Biomedica: Vol. 29 No. 4 (2009)
- Jefferson Antonio Buendía, Attitudes, knowledge and beliefs of patient about anti-hypertensive drugs , Biomedica: Vol. 32 No. 4 (2012)
- Carlos A. Isaza, Franciso J. Osorio, Giovanny Mesa, Juan C. Moncada, Patterns of antihypertensive agents use in 11,947 Colombian patients. , Biomedica: Vol. 22 No. 4 (2002)
- Diana María Valencia, Carlos Andrés Naranjo, María Victoria Parra, María Antonieta Caro, Ana Victoria Valencia, Carlos José Jaramillo, Gabriel Bedoya, Association and interaction of AGT, AGTR1, ACE, ADRB2, DRD1, ADD1, ADD2, ATP2B1, TBXA2R and PTGS2 genes on the risk of hypertension in Antioquian population , Biomedica: Vol. 33 No. 4 (2013)
- Germán Briceño, Monica Fernández, Jaime Céspedes, High prevalence of cardiovascular disease risk factors in a pediatric population , Biomedica: Vol. 35 No. 2 (2015)
- Deivis Nicolás Guzmán-Tordecilla, Andrés Ignacio Vecino-Ortiz, Diego Lucumí, Graciela Mentz, Chronic stress as a mediator of the relationship between socioeconomic status and pharmacological adherence in hypertensive patients , Biomedica: Vol. 40 No. 2 (2020)
- Catalina Cáceres , Álvaro José Lora , Silvia Juliana Villabona , María Catalina Rocha , Paul Anthony Camacho, Adherence to pharmacological treatment in non-communicable chronic diseases in the Colombian population: Systematic review and meta-analysis , Biomedica: Vol. 43 No. Sp. 3 (2023): Enfermedades crónicas no transmisibles
- Ludwing Ricardo Marín , Lina María Vera , Boris Eduardo Vesga , Mabelyn Solany Marín, Relationship of quality and duration of sleep with arterial hypertension in a Colombian population , Biomedica: Vol. 44 No. Sp. 1 (2024): Enfermedades crónicas no transmisibles

Copyright (c) 2024 Biomedica

This work is licensed under a Creative Commons Attribution 4.0 International License.
Article metrics | |
---|---|
Abstract views | |
Galley vies | |
PDF Views | |
HTML views | |
Other views |